WHITEHOUSE STATION, N.J. — Merck & Co., Inc., today announced the availability of HYZAAR(R) 100-12.5 mg (losartan potassium/hydrochlorothiazide tablets), a new tablet that combines the once-daily efficacy of 100 mg COZAAR(R) (losartan potassium tablets) with a low-dose diuretic to provide greater convenience and enhance titration options within the losartan family. HYZAAR 100-12.5 mg contains 100 mg of losartan and 12.5 mg of hydrochlorothiazide (HCTZ).
The addition of HYZAAR 100-12.5 mg to the losartan family of medicines offers a new, convenient titration step for doctors treating hypertension in patients whose blood pressure is not adequately controlled by COZAAR 100 mg. HYZAAR 100-12.5 mg, now available at pharmacies, is available by prescription only and is priced the same as COZAAR 100 mg.

Related Results

Merck & Co’s Cozaar gets US approval for stroke prevention.

Panel adds to uses for drug. (Digest).(Cozaar approved as therapy for reducin…

Merck Reports First-Quarter 2008 Financial Results

Bellwether Report.com is Looking at Merck & Co. Inc.

Hypertensive drug classes: brand names only

HYZAAR is also indicated to reduce the risk of stroke in patients with hypertension and LVH (Left Ventricular Hypertrophy)
In April 2005, the FDA approved HYZAAR to reduce the risk of stroke based on the landmark LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study. HYZAAR and COZAAR are the only angiotensin II receptor blockers (ARBs) indicated to reduce the risk of stroke in patients with hypertension and LVH. There is evidence that this benefit does not apply to black patients.
In the LIFE trial, 4,605 patients were randomized to receive once daily losartan 50 mg and 4,588 patients to receive once daily atenolol 50 mg. If goal blood pressure (
source